About NicOx

Profile
Pipeline
Medical Education Grants

Development
Naproxcinod
NCX 6560
Portfolio
Maximizing portfolio
R&D partnerships
NO-donating Research Platform
People
Board of Directors
Management Team
Contacts
Careers
Investor & media
Press releases
Investor relations
Fact file
Financials
Corporate governance
"Informations Réglementées"

Conferences
Home
Directions to NicOx
Site en français

NicOx press releases (2008-2009)
Archives (from 1996 up to date):

 Select a year                  and / or Keyword..    GO
Title
Date
• NicOx to close US headquarters
04/08/2010
• NicOx first half 2010 financial results
30/07/2010
• FDA provides Complete Response Letter to NicOx's New Drug Application for naproxcinod
22/07/2010
• Presentation of preclinical data for NicOx's ophthalmology candidate NCX 434
28/06/2010
• NicOx: Presentation at ESH congress
22/06/2010
• NicOx: Presentations at EULAR congress
21/06/2010
• NicOx: Presentation of promising preclinical results in the fields of ophthalmology and pain
01/06/2010
• NicOx provides strategic update
19/05/2010
• NicOx provides update on FDA Advisory Committee Meeting for naproxcinod
13/05/2010
• Posting of Briefing Documents for FDA Advisory Committee on NicOx's naproxcinod - Company to host conference calls on Thursday May 13
11/05/2010
• NicOx reports first quarter 2010 financial results
07/05/2010
• Pooled phase 3 blood pressure results for NicOx's naproxcinod presented at the American Society of Hypertension (ASH)
03/05/2010
• NicOx: Publication of naproxcinod phase 3 data in Osteoarthritis and Cartilage
22/03/2010
• NicOx announces FDA Advisory Committee to discuss naproxcinod on May 12
08/03/2010
• NicOx 2009 Financial Results
04/03/2010
• NicOx and Bausch + Lomb Announce Worldwide Licensing Agreement for NCX 116
03/03/2010
• NicOx announces EMEA validation of naproxcinod MAA submission
22/01/2010
• NicOx and TOPIGEN Pharmaceuticals terminate collaboration following the acquisition of TOPIGEN by Pharmaxis
12/01/2010
• NicOx submits naproxcinod MAA to the EMEA
22/12/2009
• NicOx announces FDA accepts naproxcinod NDA for filing
18/11/2009
• NicOx announces NCX 6560 meets primary and secondary objectives in first-in-man study
13/11/2009
• Report of NicOx’s financial results for the first three quarters of 2009
22/10/2009
• NicOx presents 26 week naproxcinod efficacy data at American College of Rheumatology
20/10/2009
• NicOx submits New Drug Application (NDA) for naproxcinod to the US FDA
25/09/2009
• Important data for NicOx’ naproxcinod published in the American Journal of Cardiology
22/09/2009
• NicOx makes three scientific presentations at the 2009 World Congress on Osteoarthritis
14/09/2009
• NicOx reacquires rights to PF-03187207 for glaucoma from Pfizer
06/08/2009
• NicOx first half 2009 financial results: naproxcinod nearing regulatory submissions in US and Europe
29/07/2009
• NicOx: additional 24 hour blood pressure results for naproxcinod presented at the European Meeting on Hypertension
15/06/2009
• NicOx presents naproxcinod results in several posters at EULAR
12/06/2009
• NicOx publishes results of the ZEST phase 2 study for naproxcinod
09/06/2009
• NicOx presents phase 3 quality of life data for naproxcinod at ISPOR
19/05/2009
• NicOx reports first quarter 2009 financial results
13/05/2009
• Analyses of phase 3 blood pressure data for NicOx’ naproxcinod presented at ASH
07/05/2009
• NicOx co-presents four posters on PF 03187207 for glaucoma at ARVO with Pfizer Inc
05/05/2009
• NicOx acquires Nitromed’s NO-donating patents
23/04/2009
• New analyses of phase 3 data for NicOx’ naproxcinod presented at the American College of Cardiology (ACC) Annual Meeting
31/03/2009
• NicOx initiates proof-of-principle clinical study for NCX 6560
18/03/2009
• Financial results for full year 2008: NicOx in a unique position to deliver significant shareholder value
26/02/2009
Click here to be added to our mailing list
  Printable version
Archives (from 1996 up to date)  GO
For more information :  
NicOx: +33 (0)4 97 24 53 00 / communications@nicox.com

Media Relations - FD:

Media Relations Financials Dynamics
   
Europe Guillaume Granier (France) - Tel: +33 (0)1 47 03 68 10 - guillaume.granier@fd.com
Stéphanie Bia (France) - Tel: +33 (0)1 47 03 68 10 - stephanie.bia@fd.com
Jonathan Birt (UK) - Tel +44 (0)20 7269 7205 - jonathan.birt@fd.com
   
United States Robert Stanislaro - Tel +1 212 850 5657 - robert.stanislaro@fd.com
Irma Gomez-Dib - Tel +1 212 850 5761- irma.gomez-dib@fd.com